PFE logo

Pfizer (PFE) Accounts receivable

Annual accounts receivable:

$11.46B-$103.00M(-0.89%)
December 31, 2024

Summary

  • As of today (May 29, 2025), PFE annual accounts receivable is $11.46 billion, with the most recent change of -$103.00 million (-0.89%) on December 31, 2024.
  • During the last 3 years, PFE annual accounts receivable has fallen by -$16.00 million (-0.14%).
  • PFE annual accounts receivable is now -21.73% below its all-time high of $14.64 billion, reached on December 31, 2009.

Performance

PFE Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPFEbalance sheet metrics

Quarterly accounts receivable:

$11.85B+$382.00M(+3.33%)
March 29, 2025

Summary

  • As of today (May 29, 2025), PFE quarterly accounts receivable is $11.85 billion, with the most recent change of +$382.00 million (+3.33%) on March 29, 2025.
  • Over the past year, PFE quarterly accounts receivable has increased by +$856.00 million (+7.79%).
  • PFE quarterly accounts receivable is now -26.32% below its all-time high of $16.08 billion, reached on September 1, 2022.

Performance

PFE Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPFEbalance sheet metrics

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

PFE Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-0.9%+7.8%
3 y3 years-0.1%-10.4%
5 y5 years+69.3%+19.9%

PFE Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-0.9%+4.7%-26.3%+15.8%
5 y5-year-0.9%+69.3%-26.3%+49.7%
alltimeall time-21.7%+138.9%-26.3%+146.9%

PFE Accounts receivable History

DateAnnualQuarterly
Mar 2025
-
$11.85B(+3.3%)
Dec 2024
$11.46B(-0.9%)
$11.46B(-20.7%)
Sep 2024
-
$14.45B(+26.8%)
Jun 2024
-
$11.39B(+3.7%)
Mar 2024
-
$10.99B(-5.0%)
Dec 2023
$11.57B(+5.6%)
$11.57B(+4.3%)
Sep 2023
-
$11.09B(+8.4%)
Jun 2023
-
$10.23B(-16.9%)
Mar 2023
-
$12.30B(+12.4%)
Dec 2022
$10.95B(-4.6%)
$10.95B(-31.9%)
Sep 2022
-
$16.08B(+6.1%)
Jun 2022
-
$15.15B(+14.6%)
Mar 2022
-
$13.22B(+15.2%)
Dec 2021
$11.48B(+45.1%)
$11.48B(-3.5%)
Sep 2021
-
$11.90B(+12.4%)
Jun 2021
-
$10.59B(+7.3%)
Mar 2021
-
$9.86B(+24.7%)
Dec 2020
$7.91B(+16.8%)
$7.91B(-21.0%)
Sep 2020
-
$10.01B(+9.7%)
Jun 2020
-
$9.13B(-7.6%)
Mar 2020
-
$9.88B(+45.9%)
Dec 2019
$6.77B(-15.6%)
$6.77B(-28.3%)
Sep 2019
-
$9.44B(-3.6%)
Jun 2019
-
$9.79B(+2.0%)
Mar 2019
-
$9.60B(+19.6%)
Dec 2018
$8.03B(-2.4%)
$8.03B(-19.9%)
Sep 2018
-
$10.02B(+1.5%)
Jun 2018
-
$9.87B(+4.5%)
Mar 2018
-
$9.45B(+15.0%)
Dec 2017
$8.22B(-0.0%)
$8.22B(-17.8%)
Sep 2017
-
$10.00B(+5.6%)
Jun 2017
-
$9.48B(+6.6%)
Mar 2017
-
$8.89B(+8.1%)
Dec 2016
$8.22B(+0.6%)
$8.22B(-16.4%)
Sep 2016
-
$9.84B(+7.6%)
Jun 2016
-
$9.14B(+1.2%)
Mar 2016
-
$9.03B(+10.5%)
Dec 2015
$8.18B(-2.7%)
$8.18B(-14.3%)
Sep 2015
-
$9.54B(+6.5%)
Jun 2015
-
$8.95B(+0.3%)
Mar 2015
-
$8.92B(+6.2%)
Dec 2014
$8.40B(-10.2%)
$8.40B(-15.6%)
Sep 2014
-
$9.96B(-4.2%)
Jun 2014
-
$10.39B(+10.5%)
Mar 2014
-
$9.40B(+0.4%)
Dec 2013
$9.36B(-12.3%)
$9.36B(-17.7%)
Sep 2013
-
$11.37B(-1.3%)
Jun 2013
-
$11.52B(-9.5%)
Mar 2013
-
$12.73B(+19.3%)
DateAnnualQuarterly
Dec 2012
$10.68B(-18.2%)
$10.68B(-14.8%)
Sep 2012
-
$12.52B(-2.8%)
Jun 2012
-
$12.88B(-9.2%)
Mar 2012
-
$14.18B(+8.6%)
Dec 2011
$13.06B(-10.6%)
$13.06B(-17.1%)
Sep 2011
-
$15.75B(+3.7%)
Jun 2011
-
$15.19B(+0.1%)
Mar 2011
-
$15.18B(+3.9%)
Dec 2010
$14.61B(-0.2%)
$14.61B(+2.2%)
Sep 2010
-
$14.30B(+2.1%)
Jun 2010
-
$14.01B(+2.9%)
Mar 2010
-
$13.61B(-7.1%)
Dec 2009
$14.64B(+63.5%)
$14.64B(+38.8%)
Sep 2009
-
$10.55B(+1.0%)
Jun 2009
-
$10.45B(+8.9%)
Mar 2009
-
$9.60B(+7.1%)
Dec 2008
$8.96B(-9.0%)
$8.96B(-9.5%)
Sep 2008
-
$9.90B(-3.4%)
Jun 2008
-
$10.24B(-1.8%)
Mar 2008
-
$10.43B(+6.0%)
Dec 2007
$9.84B(+4.8%)
$9.84B(-1.0%)
Sep 2007
-
$9.94B(+4.7%)
Jun 2007
-
$9.50B(-9.2%)
Mar 2007
-
$10.46B(+11.3%)
Dec 2006
$9.39B(+3.2%)
$9.39B(+2.3%)
Sep 2006
-
$9.18B(-1.1%)
Jun 2006
-
$9.28B(-10.4%)
Mar 2006
-
$10.35B(+13.7%)
Dec 2005
$9.10B(-2.8%)
$9.10B(-2.6%)
Sep 2005
-
$9.35B(+0.3%)
Jun 2005
-
$9.32B(-7.5%)
Mar 2005
-
$10.07B(+7.5%)
Dec 2004
$9.37B(+8.5%)
$9.37B(+1.6%)
Sep 2004
-
$9.22B(-1.3%)
Jun 2004
-
$9.34B(-10.3%)
Mar 2004
-
$10.41B(+20.6%)
Dec 2003
$8.64B(+49.3%)
$8.64B(+0.1%)
Sep 2003
-
$8.63B(-2.1%)
Jun 2003
-
$8.81B(+30.3%)
Mar 2003
-
$6.76B(+16.8%)
Dec 2002
$5.79B(+20.6%)
$5.79B(-5.1%)
Sep 2002
-
$6.10B(-2.8%)
Jun 2002
-
$6.27B(-2.8%)
Mar 2002
-
$6.45B(+34.5%)
Dec 2001
$4.80B(-12.6%)
$4.80B(-15.5%)
Sep 2001
-
$5.68B(+4.5%)
Jun 2001
-
$5.43B(-5.9%)
Mar 2001
-
$5.77B(+5.2%)
Dec 2000
$5.49B(+2.3%)
$5.49B(+2.3%)
Dec 1999
$5.37B
$5.37B

FAQ

  • What is Pfizer annual accounts receivable?
  • What is the all time high annual accounts receivable for Pfizer?
  • What is Pfizer annual accounts receivable year-on-year change?
  • What is Pfizer quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Pfizer?
  • What is Pfizer quarterly accounts receivable year-on-year change?

What is Pfizer annual accounts receivable?

The current annual accounts receivable of PFE is $11.46B

What is the all time high annual accounts receivable for Pfizer?

Pfizer all-time high annual accounts receivable is $14.64B

What is Pfizer annual accounts receivable year-on-year change?

Over the past year, PFE annual accounts receivable has changed by -$103.00M (-0.89%)

What is Pfizer quarterly accounts receivable?

The current quarterly accounts receivable of PFE is $11.85B

What is the all time high quarterly accounts receivable for Pfizer?

Pfizer all-time high quarterly accounts receivable is $16.08B

What is Pfizer quarterly accounts receivable year-on-year change?

Over the past year, PFE quarterly accounts receivable has changed by +$856.00M (+7.79%)
On this page